Sign In
Buy CVKD
$4.19
-0.160 (-3.68%)
At Close: Jun 03, 2026
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference
09:00am, Thursday, 04'th Jan 2024
PONTE VEDRA, Fla. , Jan. 4, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (b
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target
09:00am, Tuesday, 19'th Dec 2023
PONTE VEDRA, Fla., Dec. 19, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization
09:00am, Tuesday, 12'th Dec 2023
PONTE VEDRA, Fla. , Dec. 12, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage, novel, oral and reversible anticoagulant
Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023
04:15pm, Thursday, 30'th Nov 2023
PONTE VEDRA, Fla. , Nov. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (
Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update
09:00am, Thursday, 09'th Nov 2023
PONTE VEDRA, Fla. , Nov. 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) ("Cadrenal Therapeutics" or the "Company") a biopharmaceutical company developing tecarfarin, a late-stage
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference
04:15pm, Monday, 09'th Oct 2023
PONTE VEDRA, Fla. , Oct. 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (b
Tecarfarin is the only known Novel Vitamin K Antagonist in Development PONTE VEDRA, Fla. , Sept. 5, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company deve
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)
08:00am, Wednesday, 30'th Aug 2023
NEW YORK , Aug. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thin
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
04:15pm, Monday, 28'th Aug 2023
PONTE VEDRA, Fla. , Aug. 28, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (b
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update
09:00am, Thursday, 10'th Aug 2023
PONTE VEDRA, Fla. , Aug. 10, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (b
Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases
09:00am, Tuesday, 01'st Aug 2023
PONTE VEDRA, Fla. , Aug. 1, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel oral and reversible antico
Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors
09:00am, Monday, 24'th Jul 2023
PONTE VEDRA, Fla. , July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral
Why Is Cadrenal Therapeutics (CVKD) Stock Up 71% Today?
08:48am, Wednesday, 12'th Jul 2023
Cadrenal Therapeutics (NASDAQ: CVKD ) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. There have been no new press releases from Cadrenal Therapeutics that
IPO Round Up of First Half of 2023
12:17pm, Wednesday, 05'th Jul 2023
Normally, IPO activity gains momentum in the second quarter and peaks in June. This year was no exception.
The 3 Hottest IPOs to Buy Before They Soar
06:23am, Wednesday, 28'th Jun 2023
It has been a tough, quiet year in the market for initial public stock offerings (IPOs) which has investors eagerly searching for high potential IPOs. In the global IPO landscape, the first quarter of
